Astellas Pharma Unspadr Stock Price To Sales
| YPHA Stock | EUR 9.45 0.10 1.07% |
ASTELLAS PHARMA UNSPADR fundamentals help investors to digest information that contributes to ASTELLAS PHARMA's financial success or failures. It also enables traders to predict the movement of ASTELLAS Stock. The fundamental analysis module provides a way to measure ASTELLAS PHARMA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ASTELLAS PHARMA stock.
ASTELLAS |
ASTELLAS PHARMA UNSPADR Company Price To Sales Analysis
ASTELLAS PHARMA's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, ASTELLAS PHARMA UNSPADR has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—General (which currently averages 0.0) industry. The price to sales for all Germany stocks is 100.0% higher than that of the company.
ASTELLAS Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ASTELLAS PHARMA's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ASTELLAS PHARMA could also be used in its relative valuation, which is a method of valuing ASTELLAS PHARMA by comparing valuation metrics of similar companies.ASTELLAS PHARMA is currently under evaluation in price to sales category among its peers.
ASTELLAS Fundamentals
| Return On Equity | 0.0971 | |||
| Return On Asset | 0.0635 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.17 % | |||
| Shares Outstanding | 1.83 B | |||
| Price To Earning | 28.51 X | |||
| Revenue | 1.41 T | |||
| Gross Profit | 1.04 T | |||
| EBITDA | 348.55 B | |||
| Net Income | 100.86 B | |||
| Cash And Equivalents | 305.99 B | |||
| Cash Per Share | 165.15 X | |||
| Total Debt | 308 M | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 905.03 X | |||
| Cash Flow From Operations | 325.33 B | |||
| Earnings Per Share | 0.57 X | |||
| Number Of Employees | 14.52 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 24.49 B | |||
| Z Score | 47.4 | |||
| Annual Yield | 0.03 % | |||
| Last Dividend Paid | 55.0 |
About ASTELLAS PHARMA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ASTELLAS PHARMA UNSPADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ASTELLAS PHARMA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ASTELLAS PHARMA UNSPADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in ASTELLAS Stock
ASTELLAS PHARMA financial ratios help investors to determine whether ASTELLAS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ASTELLAS with respect to the benefits of owning ASTELLAS PHARMA security.